Thermo Fisher Scientific CD27 (Tumor Necrosis Factor Receptor Superfamily 7) Monoclonal Antibody (LPFS2, 4177)

Applications and Tested Dilution

Product Specifications

Product Specific Information

Immunohistochemistry (PFA fixed): Incubate antibody for 30 minutes at room temperature.
Staining of formalin-fixed tissues requires heating tissue sections in 10 mM Tris with 1 mM EDTA (pH 9.0) for 45 minutes at 95°C, followed by cooling at room temperature for 20 minutes.

Target Information

CD27 is a 50 kDa member of the tumor necrosis factor (TNF) receptor superfamily that includes CD40 and CD30.
Members of the TNF receptor family regulate cell proliferation and death. CD27 and its ligand CD70 are primarily expressed in lymphocytes. High expression of CD27 depends on antigen receptor ligation, while CD70 expression requires co-stimulatory or pro-inflammatory signals.

CD27 is expressed as a disulfide-linked homodimer on mature thymocytes, peripheral blood T cells, and a subpopulation of B cells. T cell activation via the TCR-CD3 complex increases CD27 expression and releases soluble CD27 (sCD27) into plasma, urine, or spinal fluid. Soluble CD27 serves as a prognostic marker for acute and chronic B cell malignancies.

RgpA, a cysteine proteinase, can degrade CD27 and counteract T cell activation mediated by CD27-CD70 interaction. CD27-binding protein (SIVA), a proapoptotic protein, binds to CD27 and is implicated in receptor-induced apoptosis.
Diseases associated with CD27 dysfunction include Lymphoproliferative Syndrome 2 and Autosomal Recessive Lymphoproliferative Syndrome.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.